Select Publications
Journal articles
2024, 'Sharing Colorectal Cancer Follow-Up Using an E-Care Plan Between Cancer Services and Primary Health Care', Studies in Health Technology and Informatics, 310, pp. 1517 - 1518, http://dx.doi.org/10.3233/SHTI231272
,2024, 'Kiosk 9Q-FA-02 Utility of CMR in Diagnosis of Metastatic Cardiac Melanoma', Journal of Cardiovascular Magnetic Resonance, 26, pp. 100930, http://dx.doi.org/10.1016/j.jocmr.2024.100930
,2023, 'Improving Medication Safety in Cancer Services for Ethnic Minority Consumers: Protocol for a Pilot Feasibility and Acceptability Study of a Co-Designed Consumer Engagement Intervention', JMIR Research Protocols, 12, pp. e49902, http://dx.doi.org/10.2196/49902
,2023, 'Making it Meaningful : Co-designing an intervention to improve medication safety for people from culturally and linguistically diverse backgrounds accessing cancer services', Patient Experience Journal, 10, pp. 34 - 48, http://dx.doi.org/10.35680/2372-0247.1732
,2022, 'Durvalumab and multimodality therapy in a patient with multiple recurrent and unresectable cutaneous squamous cell carcinoma', Internal Medicine Journal, 52, pp. 1103 - 1104, http://dx.doi.org/10.1111/imj.15809
,2022, 'What does co-design mean for Australia's diverse clinical workforce?', Australian Health Review, 46, pp. 60 - 61, http://dx.doi.org/10.1071/AH21116
,2021, 'Codesigning consumer engagement strategies with ethnic minority consumers in Australian cancer services: The CanEngage Project protocol', BMJ Open, 11, pp. e048389, http://dx.doi.org/10.1136/bmjopen-2020-048389
,2021, 'Challenges and solutions to sharing a cancer follow-up e-care plan between a cancer service and general practice', Public Health Research and Practice, 31, http://dx.doi.org/10.17061/PHRP31122108
,2021, 'Standard-dose osimertinib in egfr-mutated non-small-cell lung adenocarcinoma with leptomeningeal disease', JCO Precision Oncology, 5, pp. 561 - 568, http://dx.doi.org/10.1200/PO.20.00464
,2020, 'Assessing suitability for long-term colorectal cancer shared care: a scenario-based qualitative study', BMC Family Practice, 21, pp. 240, http://dx.doi.org/10.1186/s12875-020-01311-w
,2020, 'Correlation between initial tumour volume and treatment duration on Dabrafenib: Observation study of subjects with BRAF mutant melanoma on the BRF112680 trial', BMC Cancer, 20, pp. 342, http://dx.doi.org/10.1186/s12885-020-06848-8
,2019, 'Development of an interactive, web-based shared care plan to facilitate the follow-up care of colorectal cancer patients', , http://dx.doi.org/10.21203/rs.2.13454/v2
,2019, '“Can I still get a tattoo?” Patients’ experiences across the clinical trajectory for metastatic melanoma: a dynamic narrative model of patient journey', Patient Experience Journal, 6, pp. 87 - 93, http://dx.doi.org/10.35680/2372-0247.1301
,2018, 'Using behaviour change and implementation science to address low referral rates in oncology', BMC Health Services Research, 18, pp. 904, http://dx.doi.org/10.1186/s12913-018-3653-1
,2018, 'The plot thickens: Archetypal narrative structure in the melanoma patient journey', Cogent Medicine, 5, pp. 1484053, http://dx.doi.org/10.1080/2331205x.2018.1484053
,2017, 'Advanced cancer patients’ attitudes towards, and experiences with, screening for somatic mutations in tumours: a qualitative study', European Journal of Cancer Care, 26, http://dx.doi.org/10.1111/ecc.12600
,2017, 'Patient, general practitioner and oncologist views regarding long-term cancer shared care.', Fam Pract, 35, pp. 323 - 329, http://dx.doi.org/10.1093/fampra/cmx105
,2017, 'Dexamethasone Modifies Cystatin C-Based Diagnosis of Acute Kidney Injury During Cisplatin-Based Chemotherapy', Kidney and Blood Pressure Research, 42, pp. 62 - 75, http://dx.doi.org/10.1159/000469715
,2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015
,2016, 'Treatment of breast cancer 2 (BRCA2)-mutant follicular dendritic cell sarcoma with a poly ADP-ribose polymerase (PARP) inhibitor: A case report', BMC Research Notes, 9, pp. 386, http://dx.doi.org/10.1186/s13104-016-2189-x
,2016, 'Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer', Oncology and Therapy, 4, pp. 103 - 116, http://dx.doi.org/10.1007/s40487-016-0020-4
,2016, 'The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study', ONCOLOGIST, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530
,2016, 'The impact of mismatch repair status in colorectal cancer on the decision to treat with adjuvant chemotherapy: An Australian population-based multicenter study', Oncologist, 21, pp. 618 - 625, http://dx.doi.org/10.1634/theoncologist.2015-0530
,2016, 'Achieving behaviour change for detection of Lynch syndrome using the Theoretical Domains Framework Implementation (TDFI) approach: A study protocol', BMC Health Services Research, 16, pp. 89, http://dx.doi.org/10.1186/s12913-016-1331-8
,2016, '198P Use of chemotherapy and mismatch repair deficiency testing in resected stage II colon cancer', Annals of Oncology, 27, http://dx.doi.org/10.1093/annonc/mdw581.031
,2015, 'TOPS: A randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue.', Journal of Clinical Oncology, 33, pp. 9571 - 9571, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.9571
,2014, 'Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436)', Clinical Cancer Research, 20, pp. 4449 - 4458, http://dx.doi.org/10.1158/1078-0432.CCR-14-0887
,2014, 'Cutaneous metastasis of prostate carcinoma treated with radiotherapy: A case presentation', BMC Research Notes, 7, pp. 505, http://dx.doi.org/10.1186/1756-0500-7-505
,2014, 'Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment', Melanoma Research, 24, pp. 408 - 412, http://dx.doi.org/10.1097/CMR.0000000000000085
,2014, 'Targeting treatment for colorectal cancer: The EGFR antibody story', Cancer Forum, 38, pp. 39 - 43
,2013, 'PLASMA CYSTATIN C IS ELEVATED IN THE ABSENCE OF ACUTE KIDNEY INJURY FOLLOWING CISPLATIN WITH CONTEMPORARY ANTIEMETICS', NEPHROLOGY, 18, pp. 41 - 41, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000323453000103&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2013, 'Use of neostigmine in capecitabine-induced paralytic ileus', Tumori, 99, http://dx.doi.org/10.1177/030089161309900518
,2013, 'Use of neostigmine in capecitabine-induced paralytic ileus', Tumori Journal, 99, pp. e225 - e228, http://dx.doi.org/10.1177/030089161309900518
,2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours.', Journal of Clinical Oncology, 30, pp. e13585 - e13585, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e13585
,2010, 'Phase i clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 65, pp. 597 - 605, http://dx.doi.org/10.1007/s00280-009-1157-8
,2010, 'Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer', Cancer Chemotherapy and Pharmacology, 65, pp. 597 - 605, http://dx.doi.org/10.107/s00280-009-1157-8
,2010, 'Rationale for treatment durations of targeted cancer agents', Lancet Oncology, 11, pp. 1113 - 1115, http://dx.doi.org/10.1016/S1470-2045(10
,2006, 'Primary pancreatic lymphoma - pancreatic tumours that are potentially curable without resection, a retrospective review of four cases', BMC Cancer, 6, pp. 117, http://dx.doi.org/10.1186/1471-2407-6-117
,1998, 'Lipid lowering therapy in patients with HIV infection (multiple letters) [3]', Lancet, 352, pp. 1782 - 1783, http://dx.doi.org/10.1016/s0140-6736(05)79858-5
,Conference Papers
2017, 'Compassionate Supply of Oncology Drugs Within the South Eastern Sydney Local Health District (SESLHD) in 2011-2015', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 188 - 188, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413954500311&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2015, 'TOPS - a randomised controlled trial of a multidisciplinary intervention for post-cancer fatigue', Chicago, presented at 2015 ASCO Annual Meeting, Chicago, 29 May 2015 - 02 June 2015
,2013, 'BARRIERS TO RECRUITMENT FOR A POST-CANCER FATIGUE INTERVENTION STUDY - THE TOPS TRIAL', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 116 - 116, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800178&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1
,2012, 'Phase I study of everolimus in combination with fluvastatin and zoledronic acid in patients with solid tumours', in Journal of clinical oncology - official journal of the American Society of Clinical Oncology, American Society of Clinical Oncology, New York, pp. e13585 - e13585, presented at ASCO Annual Meeting, Chicago, USA, 01 June 2012 - 05 June 2012, http://meeting.ascopubs.org/gca?gca=ascomtg%3B30%2F15_suppl%2Fe13585&allch=&submit=Go#abstr-1
,2011, 'Describing treatment, treatment outcomes, resource use and quality of life of advanced NSCLC patients – the Lung Cancer Economics and Outcomes Research (LUCEOR) studies.', in Journal of Thoracic Oncology, Lippincott Williams & Wilkins, USA, pp. 1404 - 1405, presented at Proceedings of the 14th World Conference on Lung Cancer, Amsterdam, http://dx.doi.org/10.1097/01.JTO.0000399290.73317.eb
,2009, 'The Financially Tolerable Dose: A New Concept in Cancer Trial Design', in Storm BL; Hasford J; Hennessy S; Park BJ (eds.), Pharmacoepidemiology and Drug Safety, John Wiley & Sons Ltd, Chichester, W Sussex, England, pp. S173 - S174
,Conference Posters
2023, 'Sharing care between specialist health services and primary health care using interactive e-care plans', Online, presented at Digital Health Forum, Online, 07 February 2023
,2021, 'Telemedicine in the context of Covid-19: A qualitativestudy of cancer patients and clinicians', presented at Clinical Oncology Society Australia Annual Scientific Meeting, 16 November 2021
,2020, 'Retrospective analysis of chemotherapy‐induced febrile neutropenia; Local experience towards risk‐based management', Virtual, Vol. 16, pp. 142 - 142, presented at Clinical Oncology Society Australia Annual Scientific Meeting, Virtual, 11 November 2020 - 13 November 2020, http://dx.doi.org/10.1111/ajco.13498
,2020, 'Clinical audit of chest drain complications in medical oncology patients', Virtual, Vol. 16, pp. 142 - 143, presented at Clinical Oncology Society Australia Annual Scientific Meeting 2020, Virtual, 11 November 2020 - 13 November 2020, http://dx.doi.org/10.1111/ajco.13498
,2017, 'WORKING WITH CLINICIANS TO IDENTIFY BARRIERS TO FAMILY CANCER CLINIC REFERRALS FOR PATIENTS AT HIGH RISK OF LYNCH SYNDROME', Florence, presented at InSIGHT 7th Biennial Meeting, Florence, 05 July 2017 - 08 July 2017, http://www.2017insight.com/
,